---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088580"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:31:37.947495+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q2 net loss $4.7M; positive SEQUEL topline for CT1812

## Summary
- Net loss of $4.7M ($0.16/sh) vs $5.8M ($0.25/sh) in Q2 2022; R&D expense $8.5M.
- Cash and equivalents $37.2M; NIA grants remaining $81.8M; cash runway through Q3 2024.
- Positive topline results from Phase 2 SEQUEL qEEG study; full data expected Q4 2023.
- 540-patient Phase 2 START trial (early Alzheimer's) recruiting; MAGNIFY dry AMD dosing started.
- Published SNAP study confirming sigma-2 receptor target engagement of CT1812.

## SEC filing metadata
- accession: 0001104659-23-088580
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/0001104659-23-088580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/tm2322819d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088580
- JSON: https://secwatch.observer/filing/0001104659-23-088580.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088580.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income net loss of $4.7 million or $(0.16) per basic and diluted share.
  - Period: the second quarter ended June 30, 2023
  - Net income: net loss of $4.7 million or $(0.16) per basic and diluted share
  - Result: reported results
  source text: The Company reported a net loss of $4.7 million or $(0.16) per basic and diluted share for the second quarter ended June 30, 2023, compared to a net loss of $5.8 million or $(0.25) per basic and diluted share during the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/0001104659-23-088580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.